Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Somycel is a leading French biotechnology company specializing in the research, development, and production of mushroom spawn (mycelium). Founded in 1944 and headquartered in Langeais, France, the company is a global pioneer in fungal genetics and the industrialization of high-quality inoculum for the mushroom industry. In 1991, Somycel was acquired by Sylvan Inc., the world's largest mushroom spawn producer, and it currently serves as a major R&D and manufacturing center for Sylvan's European operations. The company's work focuses on the selection and breeding of high-yield, disease-resistant strains of Agaricus bisporus and other edible and medicinal fungi. Additionally, Somycel is actively involved in circular bio-economy initiatives, such as the MYCOCIRCLE project, which explores the use of fungal biomass as a sustainable alternative to animal-derived ingredients in the pharmaceutical and cosmetic sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Somycel.